In our current studies, we demonstrated that inhibition of PRC1 activity by its specific small molecule inhibitor RB-3 could at least partially rescue the transcriptional defect induced by BAP1 depletion in B cell lymphoma cells. This evidence concerns the gene BAP1 and B-cell non-Hodgkin lymphoma.